Enabling patients and nations to combat COVID-19
Our proficiency in developing complex APIs such as steroids and peptides, and complex long chain synthesis helps us deliver high-quality products. It has enabled us to become trusted partners to leading innovator and generic companies in the US, Europe, Latin America, Japan, Korea and other emerging markets.
At the CPS division, we offer process and analytical development as well as formulation development in line with regulations set by the USFDA. Our endeavour is to help accelerate the journey from laboratory to market for global pharma and specialty companies worldwide by providing access to our capabilities, knowledge and experience.
Many patients globally cannot afford expensive medicines for treatment. Our Generic Formulations business addresses this urgent need by offering high-quality generic versions of innovator medicines at a fraction of the cost to over 80 countries around the world.
Patients today are increasingly looking for comfort and convenience in taking medicines and adhering to treatment protocol. Our Proprietary Products division aims to fulfil their unmet and under-met needs in these aspects. We leverage our product development, translational medicine, clinical development, regulatory and commercial expertise to do so, and over the years, we’ve built a robust portfolio of innovative products. Our primary R&D focus is on dermatology and neurology. We’ve created differentiated products for conditions such as acne, psoriasis, atopic dermatitis and warts, as well as in the areas of pain management, epilepsy and antibacterials.
Our cancer care portfolio includes cytotoxics, targeted therapies and supportive care designed to combat the disease and address side effects of treatments. Some of our achievements like the development of the world’s first recombinant human GCSF biosimilar protein, the world’s first bio-similar therapeutic monoclonal antibody, and the single-source pegfilgrastim demonstrate our cutting-edge research and development capabilities in oncology.
We have a broad range of products to treat various gastroesophageal disorders. Our flagship product Omez is one of the world’s leading brands of omeprazoles. Over the years, the R&D team has developed multiple products that treat irritable bowel syndrome, diarrhoea and constipation in adults and children. Recently, we started producing medicines to address the needs of patients suffering from Hepatitis B and Hepatitis C.
We have developed a number of drugs to support patients suffering from hypertension, including Amlodipine, Amlodipine+Atenolol combination, ACE inhibitors like Enalapril, as well as Angiotensin Receptor Blockers like Telmisartan. We also strive to make patients’ lives more comfortable with beyond-the-pill solutions for treating their conditions. For instance, we launched monthly packs of Atorvastatin and Telmisartan to improve patient compliance in managing hypertension.
Metformin, Glimepride, Glicazide and their combinations are just a few of the more well-known products in our extensive portfolio that contributes to the global war against diabetes. Our commitment to addressing patients’ concerns prompted us to develop a user-friendly dosage form of Metformin that can be swallowed easily. It helps them stick to the prescribed treatment regimen.
Our solutions for seborrheic dermatitis, psoriasis, corticosteroid-responsive dermatoses, various types of dermatitis, actinic keratosis, rosacea, warts and acne are among the best in the world. Over-the-counter products we produce for trichology and hair regrowth are also leading brands in the segment. Strictly following treatment regimens is essential to successfully treat skin diseases like acne. With this in mind, we have deployed patient programmes that make it easier for them to adhere to their prescribed medications.
Nise, our brand of Nimesulide, is one of the top 300 brands in the Indian pharmaceutical market. Apart from Nimesulide, we have a number of other products including Ketorolac as well as hyaluronic acid injections that form a significant part of our generic and branded generic portfolio. Our R&D efforts focus on creating new combinations alongside exploring alternative delivery mechanisms to improve patient comfort.
